MigVax
Vaccine for Viruses in Humans
StartupMigVax is a Qiryat Shemona-based startup in the Health Tech & Life Sciences sector, established in 2020. Vaccine for Viruses in Humans. The company has raised a total of $21.3M across 4 funding rounds, currently at the A stage. Key investors include OurCrowd, Happiness Capital. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
With $21.3M in total funding, MigVax is a A-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D.
- StageA
- ProductR&D
- ModelB2B
- Employees1-10
- HQQiryat Shemona
- DistrictNorth District
- Last Round$500K
- OurCrowd
- Happiness Capital
12 articles covered by sources including www.prweb.com,
www.einnews.com,
www.jpost.com,
www.businesswire.com,
www.timesofisrael.com.
What does MigVax do?
MigVax was established as a special purpose vehicle by Migal, which granted MigVax an exclusive, worldwide license to make, use, and practice the vaccine technology for the development, manufacture, and commercialization of vaccines for viruses in humans, starting with COVID-19. The COVID-19 vaccine project was initiated upon the interdisciplinary research team’s successful development of a vaccine against infectious bronchitis virus (IBV), an avian (poultry) coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism. Given the similarity, and following the required genetic adjustments, the same vaccination concepts should apply. MigVax’s sub-unit vaccine approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx. This method, based on the IBV vaccine, generates three types of immunological response: mucosal immunity (IgA), blood-based immunity (IgG), and cell-mediated immunity.
How much funding has MigVax raised?
MigVax has raised $21.3M in total funding across 4 rounds. The company is currently at the A stage. Key investors include OurCrowd, Happiness Capital.
What sector is MigVax in?
MigVax operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is MigVax located?
MigVax is based in Tarshish Street 5, Kiryat Shmona, Israel, North District.